Lupin secures FDA nod for generic Sutab tablets with 180-day exclusivity
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals
The ruling comes against the backdrop of a mounting trauma burden in India, where nearly 4.67 lakh accidental deaths occur annually
Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
The Establishment Inspection Report came following closure of a product- specific pre-approval inspection from March 2 to March 7, 2026
The new facility marks Align’s first manufacturing presence in India and its fourth globally
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
Subscribe To Our Newsletter & Stay Updated